Archer closes in on feasibility testing for kidney disease sensors
Archer Materials (ASX:AXE) has announced progress in its development of graphene field effect transistor (gFET) sensors for its Biochip technology, a platform aimed at revolutionising chronic kidney disease diagnostics. The company’s recent testing has enhanced operational stability and design, moving closer to the feasibility stages of product development. The Biochip’s gFET sensors are designed to […]
Archer closes in on feasibility testing for kidney disease sensors Read More »